HIV Treatment Strategies
The Latest
This Week in HIV Research: PrEP So White
May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.
This Week in HIV Research: How Dangerous Is Low-Level Viremia?
May 14, 2020: Recurring low-level viremia and morbidity/mortality risk; factors affecting severe bacterial infection in people with HIV; infective endocarditis cases on the rise; high rates of opioid use among U.S. veterans with HIV.
This Week in HIV Research: There’s No Such Thing as Too Much Data
May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.
This Week in HIV Research: Special Considerations
April 30, 2020: Substance use relapse following opioid therapy for chronic pain; affect of cannabis on blood-brain barrier disruptions; PrEP considerations for adolescents; updated CDC contraceptive recommendations for women at risk for HIV.
What's New in U.S. HIV Clinical Treatment Guidelines
The latest update to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of people living with HIV occurred within the pediatric treatment guidelines on April 14.
This Week in HIV Research: How to Fix Our Dwindling HIV Workforce
April 23, 2020: The corps of front-line care providers with HIV-specific experience is aging and retiring, leaving behind a growing need for quality care. We examine recent research and analysis that both describes that need and offers interventions to meet it.
Whether HIV or COVID-19, Pregnant or Lactating Cisgender Women Need to Be Included in Clinical Trials for Therapies
Dr. Shahin Lockman says to not include women in trials is unethical.
This Week in HIV Research: The Menace of Concomitance
April 16, 2020: Anticoagulants and antiretroviral boosters; durvalumab doesn't impair antiretroviral therapy; cigarette use and oral HPV incidence; using common labs to predict Kaposi sarcoma risk.
This Week in HIV Research: The Fast-Acting Power of Integrase
April 9, 2020: Rapid efficacy of integrase-based treatment; a potent PrEP ad campaign in Chicago; more frequent STI screening for PrEP users; Ryan White funding fuels critical rural HIV care and services.
Coronavirus Elevates Telehealth for PrEP and Routine HIV Care
Many providers are quickly moving PrEP and treatment services to telemedicine platforms due to COVID-19.